☆ 4.7 Article

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164

EUROPEAN JOURNAL OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

J. Niu et al.

Summary: The study investigated the safety and efficacy of the anti-TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy showed promising antitumor activity in patients with NSCLC and those refractory to anti-PD-1/PD-L1 treatment.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu et al.

Summary: In this study, a novel human antibody MK-4830 targeting ILT4 receptor was investigated for the treatment of advanced solid tumors. Monotherapy and combination therapy with pembrolizumab were examined. The results showed that MK-4830 as monotherapy and in combination with pembrolizumab were well tolerated and demonstrated target engagement and antitumor activity. Combination therapy exhibited higher sensitivity to T-cell inflammation compared to monotherapy.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Diaz et al.

Summary: The final overall survival analysis of the KEYNOTE-177 study showed that while pembrolizumab continued to demonstrate durable antitumor activity and fewer treatment-related adverse events compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, there was no statistically significant difference in overall survival between the two treatment groups.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

T. Andre et al.

Summary: This study confirms the long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC, with a manageable safety profile.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

T. Andre et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

R. Perets et al.

Summary: The study investigated the combination therapy of the novel anti-CTLA-4 antibody Quavonlimab with pembrolizumab in patients with advanced solid tumors and NSCLC, focusing on safety, tolerability, and efficacy. Results showed that Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile compared to other dosing schedules.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC

Roy S. Herbst et al.

Summary: In patients with advanced NSCLC with PD-L1 TPS >= 50% and >= 1%, pembrolizumab continues to provide long-term benefit compared to docetaxel, with significant improvement in overall survival rates after 5 years. The findings confirm pembrolizumab as a standard-of-care treatment in the second-line or later setting.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Raphael Colle et al.

Summary: The study found that 10% of patients with MSI/dMMR mCRC treated with ICIs experienced PSPD, with most of them occurring within the first 3 months, representing the majority of primary radiological PDs. There were almost no occurrences of PSPD after 3 months.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

Romain Cohen et al.

Summary: Microsatellite instability (MSI) is a tumor phenotype related to a deficient DNA mismatch repair system (dMMR). This phenotype, observed in 5% of metastatic mCRC but 10-18% of localized CRC, is associated with high tumor mutational burden with highly immunogenic neoantigens. It has emerged as a major predictive biomarker for the efficacy of ICIs.

CANCERS (2021)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

Gilberto de Castro et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

Alexander M. Eggermont et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Elena Garralda et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Perspectives on Immunotherapy of Metastatic Colorectal Cancer

Yongjiu Dai et al.

Summary: Colorectal cancer, especially liver metastasis, remains a worldwide challenge. The emergence of immunotherapy has shown promise for mCRC patients with dMMR, but faces challenges for MSS tumors. More clinical trials are needed to further explore immunotherapy for mCRC patients, especially those with MSS.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Colorectal cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

O. Hamid et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

Laetitia Marisa et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

添加到收藏夹

Article Oncology

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

Laetitia Marisa et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

添加到收藏夹

Article Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer

Hisato Kawakami et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Robert J. Mayer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer

M. Peeters et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Sabine Venderbosch et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Medicine, General & Internal

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey et al.

LANCET (2013)

添加到收藏夹

Article Oncology

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.